CDA recommends public reimbursement of Blenrep(R): A step forward for Canadians living with myeloma

MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...
Cantech Letter

CDA recommends public reimbursement of Blenrep®: A step forward for Canadians living with myeloma

MONTREAL, Nov. 13, 2025 /CNW/ – Myeloma Canada welcomes the Canadian Drug Agency’s (CDA) two positive recommendations for the ...

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refract…

NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –– Acute unmet need in R/R ...
The Munich Eye

New Bispecific Antibody Linvoseltamab Now Available for Multiple Myeloma Treatment

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
Cochrane

Does treatment with thiazolidinediones prevent complications for people with chronic kidney disease and type 2 diabetes?

Thiazolidinediones are medications that reduce blood glucose levels and are now used to help people with chronic kidney disease (CKD: defined as long-term damage to the kidneys that reduces their ...

Gilead Provides Update on Phase 3 ASCENT-07 Study

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.